Announcement on the record date for the
capital increase of Employee Restricted Shares and
related matters
Date of events
2022/07/26
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/07/26
2.Company name:PharmaEngine, Inc.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):head office
4.Reciprocal shareholding ratios:Not applicable
5.Cause of occurrence:
(1)On May 27, 2022, annual shareholders meeting approved the issuance of
100,000 Employee Restricted Shares at a par value of NT$10 per share and
an issue price of NT$0 per share, which was reported as effective by the
Financial Supervisory Commission in its Letter Financial-Supervisory-
Securities-Corporate No. 1110348386 dated July 8, 2022.
(2)On July 26, 2022, Board of Directors approved the issuance of Employee
Restricted Shares based on" The issuance rules of Employee Restricted
Shares" and had set the record date of capital increase to July 29, 2022.
(3)The actual number of shares issued on the record date of capital
increase was 90,000 shares.
6.Countermeasures:None
7.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEngine Inc. published this content on 26 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2022 09:18:05 UTC.
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,
PHARMAENGINE, INC. 
